Results 251 to 260 of about 2,398,808 (296)
Some of the next articles are maybe not open access.
Antibody–Drug Conjugates for Immunology
Journal of Medicinal Chemistry, 2022The application of antibody-drug conjugates (ADCs) to fields outside of oncology is increasing but is still relatively uncommon. A recent publication describes the conjugation of glucocorticoid receptor modulators to antibodies as a means of improving the separation between desired anti-inflammatory activity and unwanted systemic side effects.
openaire +2 more sources
Antibody–Drug Conjugates in Uro-Oncology
Targeted Oncology, 2022Currently available treatment options for patients with refractory metastatic prostate, bladder, or kidney cancers are limited with the prognosis remaining poor. Advances in the pathobiology of tumors has led to the discovery of cancer antigens that may be used as the target for cancer treatment.
Dawid Sigorski +3 more
openaire +2 more sources
The Promise of Antibody–Drug Conjugates
New England Journal of Medicine, 2012The promise of antibody–drug conjugates (ADCs) is the specific targeting of highly potent cytotoxic agents to malignant disease without adversely affecting normal tissues. We may be on the verge of fulfilling that promise. This moment has been more than 25 years in the making and has required technology development in every facet of the conception and ...
Beverly A, Teicher, James H, Doroshow
openaire +2 more sources
Antibody–drug conjugates for cancer
The Lancet, 2019Antibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC is designed to selectively deliver the ultratoxic payload directly to the target cancer cells.
Cindy H, Chau +2 more
openaire +2 more sources
Antibody-Drug Conjugate Targets
Current Cancer Drug Targets, 2009The requirements for a cell surface molecule to be suitable as an antibody-drug conjugate target are stringent. The notion that antibodies-directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The history of antibody-drug conjugates has been marked by hurdles identified and overcome. Early conjugates used
openaire +2 more sources
Antibody–Drug Conjugate Payloads
2013Toxin payloads, or drugs, are the crucial components of therapeutic antibody-drug conjugates (ADCs). This review will give an introduction on the requirements that make a toxic compound suitable to be used in an antitumoral ADC and will summarize the structural and mechanistic features of four drug families that yielded promising results in preclinical
Jan, Anderl +3 more
openaire +2 more sources
Antibody–Drug Conjugates in Tumor Therapy
Pharmaceutical Patent Analyst, 2012Antibody-drug conjugates (ADCs) for tumor therapy contain a cytotoxic drug conjugated to a monoclonal antibody (mAb) across a linker. A homing device, the mAb enables the recognition of tumor cells by binding to tumor-specific antigens. The linker is usually cleaved inside the tumor cell or close to the cell surface according to a well-designed ...
Sammet, Benedikt +2 more
openaire +3 more sources
Payloads of Antibody: Drug Conjugates
2015The payload of antibody–drug conjugates (ADCs) is the warhead of ADCs that kills the tumor cells. Three classes of highly potent toxins including maytansinoids, auristatins, and calicheamicins are currently being employed or pursued in the clinic as the payloads of ADCs.
openaire +1 more source
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Shanu Modi +2 more
exaly
Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer
International Journal of Molecular Sciences, 2022Min-Duk Seo, Sang Gyu Park
exaly